Zusammenfassung
Patienten mit Persönlichkeitsstörungen werden heute überwiegend auch psychopharmakologisch behandelt. Dabei fehlen bislang klare, empirisch begründete Therapiestrategien. Vielmehr herrscht ein symptombezogener und pragmatischer Ansatz vor. Dieser Artikel wirft auf breiter empirischer Basis (Daten des AMSP-Projektes) ein Licht auf die aktuelle psychopharmakologische Behandlung dieser Störungsbilder in Deutschland und geht Veränderungstrends in den letzten Jahren nach.
Abstract
To a large extent, patients with personality disorders nowadays will receive psychopharmacological treatment as well as psychotherapy. Empirical founded data are still rare and a symptomatic and rather pragmatic approach dominates. This study provides an empirical insight in the psychopharmacological practice of psychiatric institutions in Germany. The use of psychotropic drugs in patients with personality disorders will be demonstrated using the data base of the AMSP drug safety program. Recent changes will be shown by comparing the results of the year 2002 against 1996.
Schlüsselwörter
Persönlichkeitsstörungen - Psychopharmakologie - Pharmakoepidemiologie
Key words
Personality Disorders - psychopharmacology - pharmacoepidemiology
Literatur
-
1
Synder S.
The interaction of psychopharmacology and psychoanalysis in the borderline patient.
Psychiatr Q.
1980;
52
240-250
-
2
Zisook S, Ricketts J E.
Psychopharmacologic approaches to the borderline patient.
Hillside J Clin Psychiatry.
1998;
10
55-70
-
3
Cowdry R W.
Psychopharmacology of borderline personality disorder.
J Clin Psychiatry.
1987;
48
15-25
-
4
Cowdry R W, Gardner D L.
Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine and tranylcyclopromine.
Arch Gen Psychiatry.
1988;
45
111-119
-
5
Dulz B.
Pharmakotherapie bei Borderlinestörungen. Eine Literaturübersicht.
Nervenarzt.
1994;
65
755-761
-
6
Soloff P H.
Algorithms for psychopharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation.
Bull Meninger Clin.
1998;
62
195-214
-
7
Soloff P H.
Psychopharmacology of borderline personality disorder.
Psychiatr Clin North Am.
2000;
23
169-192
-
8 Links P S, Heslegrave R, Villella J. Psychopharmacological management of personality disorders: an outcome-focused model. In: Silk KR (eds.). Biology of Personality Disorders. Washington: American Psychiatric Press 1998: 93-127
-
9
Links P S, Boggild A, Sarin N.
Psychopharmacology of personality disorders: review and emerging issues.
Curr Psychiatry Rep.
2001;
3
70-76
-
10
Benjamin L S.
Special feature: personality disorders: models for treatment and strategies for treatment development.
J Personal Disord.
1997;
11
307-324
-
11
Kampfhammer H P, Hippius H.
Special feature: pharmacotherapy in personality disorders.
J Personal Disord.
1998;
12
277-288
-
12
Pelissolo A, Lepine J P.
Pharmacotherapy in personality disorders: methodological issues and results.
Encephale.
1999;
25
496-507
-
13
Montgomery S A.
The psychopharmacology of borderline personality disorders.
Acta Psychiatr Belg.
1987;
87
260-266
-
14
Villalba R, Harrington C J.
Repetitive self-injurious behaviour: a neuropsychiatric perspective and review of pharmacologic treatments.
Semin Clin Neuropsychiatry.
2000;
5
214-226
-
15
Links P S, Boggild A, Sarin N.
Modeling the relationship between affective liability, impulsivity, and suicidal behavior.
J Psychiatr Pract.
2000;
6
247-255
-
16
Grohmann R, Ruether E, Engel R R, Hippius H.
Assessment of adverse drug reactions in psychiatric patients with the AMSP drug safety program.
Pharmacopsychiat.
1999;
32
21-28
Dr. Martin Heinze
Klinik für Psychiatrie und Psychotherapie · Landesklinik Teupitz
Buchholzer Str. 21
15755 Teupitz
eMail: m.heinze@lk-teupitz.de
